INM InMed Pharmaceuticals Inc.
Mergers ·
Holders of record on November 5, 2026 would get one CVR per share, but only if shareholders approve a return of capital proposal on November 4. The company had $2.2 million in cash at June 30, 2026.
Shareholders' equity of $1,075,007 in the 10-K for the year ended June 30, 2026 fell below the $2,500,000 Nasdaq minimum. The company has 45 calendar days to submit a plan.
InMed and privately held Mentari Therapeutics signed a definitive merger agreement, alongside a concurrent US$290 million private placement for the combined company.
InMed reported a net loss of $3.0 million for the quarter ended March 31, 2026, and cash, cash equivalents and short-term investments of $5.2 million, as it winds down its commercial operations.
InMed agreed to amend the exercise prices on preferred investment options held by Sabby Volatility Warrant Master Fund, Ltd. and affiliates of H.C. Wainwright & Co., LLC to $0.80 per share.
Nasdaq told InMed on March 27, 2026 that its shares closed below $1.00 for 30 consecutive trading days. The company has 180 calendar days to regain compliance and keeps trading as INM.
InMed's board approved exiting BayMedica's sales on March 4, 2026. The company calls BayMedica its only revenue-generating business, expects about $550,000 in severance costs and about $120,000 in other spending, and its annual report already carries a going-concern warning.
A single institutional investor is buying 1,952,363 shares or pre-funded warrants plus options on the same number of shares. H.C. Wainwright is placement agent.
InMed Pharmaceuticals Inc. is a pharmaceutical drug development company with a pipeline of proprietary small molecule drug candidates that are preferential signaling ligands of the CB1 and CB2 cannabinoid receptors, as well as other receptor targets linked to human disease. On March 4, 2026, its board approved winding down BayMedica's commercial operations, the only revenue-generating business of the company, and BayMedica had wound down all operating activities by June 30, 2026. The remaining work is preclinical development of three product candidates. INM-901 is a candidate for Alzheimer's disease, where the company reports reduced neuroinflammation in preclinical models and has a pre-IND meeting with the FDA scheduled for the third quarter of calendar 2026. INM-089 is being developed for dry age-related macular degeneration. The company has also completed a Phase 2 trial of INM-755 (cannabinol) cream for epidermolysis bullosa, which showed enhanced anti-itch activity compared with a control cream. The text says these priorities apply if a merger is not consummated, and that further development requires additional financing. As of September 1, 2026, the company had 6 full-time employees.
| Product or program | What it is | Stage |
|---|---|---|
| INM-901 | Small molecule candidate for Alzheimer's disease that reduces neuroinflammation | Preclinical; pre-IND meeting scheduled for third quarter of calendar 2026 |
| INM-089 | Candidate for dry age-related macular degeneration with neuroprotective effects | Preclinical |
| INM-755 (cannabinol) cream | Topical cream for symptoms related to epidermolysis bullosa | Phase 2 clinical trial completed |
| Line | FY ended Jun 30, 2026 | FY ended Jun 30, 2025 |
|---|---|---|
| Revenue | $4.9 million | |
| Research and development | $3.0 million | $2.8 million |
| Net income (loss) | -$12.6 million | -$8.2 million |
| Cash from operations | -$8.6 million | -$8.1 million |
| Cash and equivalents | $2.2 million | $10.7 million |
| Short-term investments | $39,670 | $43,384 |
Our latest story on this, dated Mar 6, 2026: "InMed Pharmaceuticals to wind down BayMedica, its only revenue-generating business". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 19, 2026: "InMed agrees to all-stock merger with Mentari Therapeutics". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 18, 2026: "InMed receives Nasdaq notice on minimum shareholders' equity". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 27, 2026: "InMed sets November 5 record date for CVRs tied to Mentari merger". The story links the filing or release it is based on. Read the story.
InMed Pharmaceuticals Inc. trades under the ticker INM on NASDAQ.
InMed Pharmaceuticals Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:MWG.
The SEC Central Index Key (CIK) for InMed Pharmaceuticals Inc. is 1728328. Its filings are on SEC EDGAR.
5,493,735 shares as of 2026-09-02, per the cover page of its 10-K filed 2026-09-09.
Our directory records InMed Pharmaceuticals Inc. under Canada.
Our directory classifies InMed Pharmaceuticals Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for InMed Pharmaceuticals Inc. is CA4576377002.
aibio.space lists InMed Pharmaceuticals Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as A1.
InMed Pharmaceuticals Inc. is a pharmaceutical drug development company with a pipeline of proprietary small molecule drug candidates that are preferential signaling ligands of the CB1 and CB2 cannabinoid receptors, as well as other receptor targets linked to human disease. On March 4, 2026, its board approved winding down BayMedica's commercial operations, the only revenue-generating business of the company, and BayMedica had wound down all operating activities by June 30, 2026.
INM-901: Small molecule candidate for Alzheimer's disease that reduces neuroinflammation Stage: Preclinical; pre-IND meeting scheduled for third quarter of calendar 2026.
Filed documents for a merger or acquisition. SEC Form 425. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.03,8.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,5.01,5.02,7.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 1.01,4.01,5.07,9.01). Source
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,7.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,7.01,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio